Aptevo Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 40

Market Cap: -

Website

Introduction: Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Clinical Trials

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: APVO436
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2024-10-09

Last Posted Date: 2025-05-11

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 39

Registration Number: NCT06634394

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Kansas, Fairway, Kansas, United States

and more 4 locations

ALG.APV-527 First-in-human Study

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: ALG.APV-527

First Posted Date: 2023-07-07

Last Posted Date: 2023-07-07

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 56

Registration Number: NCT05934539

Locations: 🇺🇸
Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

Phase 1

Withdrawn

Conditions: AML

Interventions: Biological: APVO436

First Posted Date: 2021-07-22

Last Posted Date: 2021-12-01

Lead Sponsor: Aptevo Therapeutics

Registration Number: NCT04973618

Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Phase 1

Terminated

Conditions: Psoriasis
Ulcerative Colitis

Interventions: Biological: APVO210
Biological: Placebo

First Posted Date: 2018-12-07

Last Posted Date: 2021-05-19

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 85

Registration Number: NCT03768219

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Biological: ES414

First Posted Date: 2014-10-13

Last Posted Date: 2019-08-28

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 35

Registration Number: NCT02262910

Locations: 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 4 locations

Phase 1b Safety and Efficacy Study of TRU-016

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Peripheral T-cell Lymphoma

Interventions: Biological: 20 mg/kg TRU-016 + Rituximab
Biological: 10 mg/kg TRU-016 + Rituximab
Biological: TRU-016 6-20 mg/kg + idelalisib + rituximab
Biological: TRU-016 10-20 mg/kg + ibrutinib
Biological: TRU-016 20 mg/kg + Obinutuzumab
Biological: TRU-016 10-20 mg/kg + bendamustine

First Posted Date: 2012-07-19

Last Posted Date: 2021-05-20

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 87

Registration Number: NCT01644253

Locations: 🇺🇸
Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
Greenville Health System, Greenville, South Carolina, United States
🇺🇸
Swedish Cancer Institute,1221 Madison St., Seattle, Washington, United States

and more 2 locations

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Phase 1

Completed

Conditions: B-cell Small Lymphocytic Lymphoma Recurrent

Interventions: Drug: TRU-016
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2011-03-17

Last Posted Date: 2017-06-28

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 12

Registration Number: NCT01317901

Locations: 🇺🇸
Site Reference ID/Investigator# 61523, Omaha, Nebraska, United States
🇺🇸
Site Reference ID/Investigator# 61542, Augusta, Georgia, United States
🇺🇸
Site Reference ID/Investigator# 61522, Hackensack, New Jersey, United States

and more 3 locations